Stocksigma LogoStocksigma Logo

Glenmark's IGI to Present Updated ISB 2001 Multiple Myeloma Data at ASH

Ichnos Glenmark Innovation announced an oral presentation of updated Phase 1 TRIgnite-1 data for ISB 2001 (ABBV-2001) at the 68th ASH Annual Meeting on

Glenmark's IGI to Present Updated ISB 2001 Multiple Myeloma Data at ASH

Glenmark Pharmaceuticals Ltd 路 Press Release 路 05 Nov 2026, 1:12 am

Glenmark's IGI to Present Updated ISB 2001 Multiple Myeloma Data at ASH Ichnos Glenmark Innovation announced an oral presentation of updated Phase 1 TRIgnite-1 data for ISB 2001 (ABBV-2001) at the 68th ASH Annual Meeting on 12th Dec'26. The investigational, first-in-class CD38 脳 BCMA 脳 CD3 trispecific T-cell engager targets relapsed/refractory multiple myeloma. New findings show robust efficacy and tolerability across longer dose-escalation follow-ups and early dose-expansion cohorts in heavily pretreated patients. ISB 2001 is being co-developed under an exclusive global licensing pact formed with AbbVie in Jul'25.

Original exchange filing (PDF)

More announcements from Glenmark Pharmaceuticals Ltd

All Glenmark Pharmaceuticals Ltd announcements